References
- Vogiatzi P, Cassone M, Claudio L et al. Targeted therapy for advanced prostate cancer: looking through new lenses. Drug News Perspect.22(10), 593–601 (2009).
- Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol.26(28), 4563–4571 (2008).
- Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br. J. Cancer100(5), 671–675 (2009).
- Attard G, Reid AH, Olmos D et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res.69(12), 4937–4940 (2009).
- Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol.28(9), 1489–1495 (2010).
- Olmos D, Arkenau HT, Ang JE et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann. Oncol.20(1), 27–33 (2009).
- Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell16(6), 458–462 (2009).
- Brodie A, Njar V, Macedo LF et al. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol. Oncol.27(1), 53–63 (2009).
- Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1–2 study. Lancet375(9724), 1437–1446 (2010).
- Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol.28(9), 1481–1488 (2010).
- Pinto-Bazurco Mendieta MA, Negri M et al. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J. Med. Chem.51(16), 5009–5018 (2008).
- Hu Q, Negri M, Jahn-Hoffmann K et al. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17) – part II: core rigidification and influence of substituents at the methylene bridge. Bioorg. Med. Chem.16(16), 7715–7727 (2008).
- Greco A, Di Benedetto A, Howard CM et al. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol. Ther.18(2), 295–306 (2010).
- Drake CG, Antonarakis ES. Update: immunological strategies for prostate cancer. Curr. Urol. Rep.11(3), 202–207 (2010).
- Irani J, Salomon L, Oba R et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol.11(2), 147–154 (2010).
Websites
- Abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy (NCT00638690) http://clinicaltrials.gov/ct2/show/NCT00638690?term=NCT00638690&rank=1
- Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (NCT00887198) http://clinicaltrials.gov/ct2/show/NCT00887198?term=NCT00887198&rank=1